Patient population
In this study, participant selection was designed to reflect real‐world patients with MS who receive ocrelizumab. Enrollment occurred on a rolling basis over a 12‐month period from active patients of the Rocky Mountain MS Center (RMMSC) at the University of Colorado Anschutz Medical Campus until the target population of 100 patients was met for the intention‐to‐treat population (ITT).Eligible patients included adults aged 18 to 55 years who: (1) had a diagnosis of RMS or PPMS as defined by the 2017 McDonald criteria;Patients were excluded from participation in this study if they experienced a serious IRR (